Literature DB >> 20842321

Role of adenosine A(2A) receptors in modulating synaptic functions and brain levels of BDNF: a possible key mechanism in the pathophysiology of Huntington's disease.

Maria Teresa Tebano1, Alberto Martire, Valentina Chiodi, Antonella Ferrante, Patrizia Popoli.   

Abstract

In the last few years, accumulating evidence has shown the existence of an important cross-talk between adenosine A(2A) receptors (A(2A)Rs) and brain-derived neurotrophic factor (BDNF). Not only are A(2A)Rs involved in the mechanism of transactivation of BDNF receptor TrkB, they also modulate the effect of BDNF on synaptic transmission, playing a facilitatory and permissive role. The cAMP-PKA pathway, the main transduction system operated by A(2A)Rs, is involved in such effects. Furthermore, a basal tonus of A(2A)Rs is required to allow the regulation of BDNF physiological levels in the brain, as demonstrated by the reduced protein levels measured in A(2A)Rs KO mice. The crucial role of adenosine A(2A)Rs in the maintenance of synaptic functions and BDNF levels will be reviewed here and discussed in the light of possible implications for Huntington's disease therapy, in which a joint impairment of BDNF and A(2A)Rs seems to play a pathogenetic role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842321      PMCID: PMC5763899          DOI: 10.1100/tsw.2010.164

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  12 in total

Review 1.  Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

Authors:  P Hemachandra Reddy; Ulziibat P Shirendeb
Journal:  Biochim Biophys Acta       Date:  2011-11-04

2.  Potential drugs and methods for preventing or delaying the progression of Huntington's disease.

Authors:  Youssef Sari
Journal:  Recent Pat CNS Drug Discov       Date:  2011-05-01

3.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

4.  Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.

Authors:  Maria Rosaria Domenici; Valentina Chiodi; Mirko Averna; Monica Armida; Antonella Pèzzola; Rita Pepponi; Antonella Ferrante; Michael Bader; Kjell Fuxe; Patrizia Popoli
Journal:  Purinergic Signal       Date:  2018-05-16       Impact factor: 3.765

5.  A new drug design targeting the adenosinergic system for Huntington's disease.

Authors:  Nai-Kuei Huang; Jung-Hsin Lin; Jiun-Tsai Lin; Chia-I Lin; Eric Minwei Liu; Chun-Jung Lin; Wan-Ping Chen; Yuh-Chiang Shen; Hui-Mei Chen; Jhih-Bin Chen; Hsing-Lin Lai; Chieh-Wen Yang; Ming-Chang Chiang; Yu-Shuo Wu; Chen Chang; Jiang-Fan Chen; Jim-Min Fang; Yun-Lian Lin; Yijuang Chern
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

Review 6.  A showcase of bench-to-bedside regenerative medicine at the 2010 ASNTR.

Authors:  David J Eve; Cesar V Borlongan; Paul R Sanberg
Journal:  ScientificWorldJournal       Date:  2011-10-23

7.  Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia.

Authors:  Veronica Ghiglieri; Vincenza Bagetta; Valentina Pendolino; Barbara Picconi; Paolo Calabresi
Journal:  Parkinsons Dis       Date:  2012-05-13

Review 8.  Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.

Authors:  Danielle A Simmons
Journal:  J Huntingtons Dis       Date:  2017

9.  The Effect of Endurance Training on Brain-Derived Neurotrophic Factor and Inflammatory Markers in Healthy People and Parkinson's Disease. A Narrative Review.

Authors:  Paulina Małczyńska-Sims; Małgorzata Chalimoniuk; Anna Sułek
Journal:  Front Physiol       Date:  2020-11-19       Impact factor: 4.566

Review 10.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.